LRG

New Immunotherapy Approach Advances

The new treatment uses T cells, a type of immune cell that are taken from the patient’s body, genetically modified and then reinfused into the patient. These modified T cells are called chimeric antigen receptor (CAR) T cells. In previous trials with these modified T cells, tumor responses have been modest and they did not persist for long enough after being re-introduced into the patient. Using this second generation CAR T cell, Dr. Carl June and his colleagues at Penn obtained long-lasting persistence once the cells were re-introduced.

By |2019-01-18T12:05:26-05:00October 5th, 2012|News|

‘Night to Fight Cancer’ event raises almost $90,000 total

The ninth annual poker tournament, now known as the “Night to Fight Cancer” to benefit The Life Raft Group’s research programs was held at Midtown Loft on September 13, 2012. Board President Jerry Cudzil once again hosted this successful event to raise money and awareness so that someday soon we can have a cure.

By |2019-09-20T13:32:32-04:00October 1st, 2012|News|

LRG research team efforts compare well to a bigger and costlier project

How does a $2 million-a-year cancer research effort with a team of nine scientists keep pace with a $100 million-a-year project with a team of 200? Pretty well, it turns out. With the Cancer Genome Atlas project in the news lately—the New York Times recently reported on progress in its colon cancer work—we decided to compare some of its data with that of the Life Raft Group’s Research Team and its D-Day Project. Our research focuses on GIST.

By |2019-09-20T13:33:11-04:00October 1st, 2012|News|
Go to Top